Showing results (281-290 of 396) with videos related to
Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Final version of 2009 AJCC melanoma staging and classificationCharles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With BRAF Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.Pigment Cell & Melanoma Research|November 20, 2014
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cellsMarie R Webster, Mai Xu, Kathryn A Kinzler, et al.The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.JCO Precision Oncology|January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol HApril K S Salama, Victoria Wang, Erin R Macrae, et al.Pageof 40